Jade Biosciences (JBIO) said late Wednesday it plans to offer shares, or pre-funded warrants to purchase shares, in an underwritten public offering.

Jade said it intends to grant its underwriters a 30-day option to buy up to an additional 15% of the securities offered.

Net proceeds will be used among others for clinical trials, pre-clinical studies, and working capital, the clinical-stage firm said.